El-Husseini Amr, Sabry Alaa, Hassan Rashad, Sobh Mohamed
University of Kentucky, Lexington, KY, USA.
Saudi J Kidney Dis Transpl. 2013 Sep;24(5):917-24. doi: 10.4103/1319-2442.118078.
Previous studies have suggested that loss of bone mineral density (BMD) frequently occurs in patients with chronic viral liver disease, presenting with histologically proven liver cirrhosis. However, little is known about the occurrence of bone disease in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. Furthermore, to the best of our knowledge, such an effect has never been studied in pediatric renal transplant recipients. The aim of this study was to assess the impact of HCV infection on BMD in pediatric renal transplant patients. We performed a cross-sectional study to assess BMD and HCV in 83 patients who received living renal allotransplants in the Mansoura Urology and Nephrology Center between 1983 and 2005. The mean age of the study patients at transplantation was 13.4 ± 2.9 years; there were 53 males (63.9%) and 30 females (36.1%). BMD was studied using dual energy X-ray absorptiometry at various time intervals up to 16 years after transplantation (mean duration after transplantation was 48 ± 34 months, range 12- 192 months). Thirty-three patients tested positive for HCV-RNA (positive group) and 50 patients were negative (negative group), and we compared the BMD between the two groups. Before transplantation, 58 patients (69.9%) were on maintenance hemodialysis, four (4.8%) were on peritoneal dialysis and 21 (25.3%) were pre-emptive. Among the HCV-positive group, six patients (18.2%) had osteoporosis, 17 (51.5%) had osteopenia and ten (30.3%) had normal BMD. In the HCV-negative group, ten patients (20.0%) had osteoporosis, 24 (48.0%) had osteopenia and 16 (32.0%) had normal BMD. The difference was not significant between the two groups (P = 0.9). Also, there was no significant difference in the serum creatinine, calcium, phosphorus and parathormone levels between the two groups. Our results suggest that chronic HCV infection does not pose a risk for low BMD in pediatric renal transplant recipients.
以往研究表明,骨矿物质密度(BMD)降低在患有慢性病毒性肝病且经组织学证实为肝硬化的患者中经常出现。然而,对于慢性丙型肝炎病毒(HCV)感染的非肝硬化患者中骨病的发生情况知之甚少。此外,据我们所知,这种影响从未在儿科肾移植受者中进行过研究。本研究的目的是评估HCV感染对儿科肾移植患者骨矿物质密度的影响。我们进行了一项横断面研究,以评估1983年至2005年间在曼苏拉泌尿外科和肾脏病中心接受活体肾移植的83例患者的骨矿物质密度和HCV情况。研究患者移植时的平均年龄为13.4±2.9岁;其中男性53例(63.9%),女性30例(36.1%)。在移植后长达16年的不同时间间隔使用双能X线吸收法研究骨矿物质密度(移植后的平均持续时间为48±34个月,范围为12 - 192个月)。33例患者HCV - RNA检测呈阳性(阳性组),50例患者呈阴性(阴性组),我们比较了两组之间的骨矿物质密度。移植前,58例患者(69.9%)接受维持性血液透析,4例(4.8%)接受腹膜透析,21例(25.3%)为抢先移植。在HCV阳性组中,6例患者(18.2%)患有骨质疏松症,17例(51.5%)患有骨质减少症,10例(30.3%)骨矿物质密度正常。在HCV阴性组中,10例患者(20.0%)患有骨质疏松症,24例(48.0%)患有骨质减少症,16例(32.0%)骨矿物质密度正常。两组之间差异无统计学意义(P = 0.9)。此外,两组之间血清肌酐、钙、磷和甲状旁腺激素水平也无显著差异。我们的结果表明,慢性HCV感染对儿科肾移植受者低骨矿物质密度不构成风险。